Skip to Main Content

Paper Details

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.
BMJ Open Diabetes Res Care
11
2017
Author NameAffiliation
Vincent Lo ReCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Vincent Lo ReCenter for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania
Vincent Lo RePerelman School of Medicine, University of Pennsylvania
Craig W NewcombCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Qing LiuCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Stephen E KimmelCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Stephen E KimmelCenter for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania
Stephen E KimmelPerelman School of Medicine, University of Pennsylvania
Brian L StromCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Brian L StromCenter for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania
Brian L StromThe State University of New Jersey
  • 1 - 11

Datasets